Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA Vaccine Official Says RFK Jr. Nomination Is a Chance for Scientist to Make the Case for Vaccines"
Watching Shares Of Vaccine Stocks; Traders Circulate Article Titled "Top FDA Vaccine Official Says RFK Jr. Nomination Is a Chance for Scientist to Make the Case for Vaccines"
Bloomberg is also reporting that Trump is likely to pick surgeon and public health researcher Marty Makary as the next head of the FDA. Previously, Makary has criticized the agency's approval of COVID-19 booster vaccines. Additionally, he has written several op-eds on the pandemic including one claiming that the U.S. would achieve herd immunity by April 2021 and a more recent one arguing that vaccines shouldn't be recommended universally for lower-risk patients.The U.S. Food and Drug Administration's (FDA) head of vaccine safety says that President-elect Donald Trump's embrace of vaccine skeptics could be an opportunity for the science community to teach the public about the value of these life-saving drugs. However, if these efforts fail it could lead to "natural consequences."
美國食品藥品監督管理局（FDA）疫苗安全負責人表示，特朗普概念對疫苗懷疑者的支持可能是科學社區向公衆傳授這些拯救生命藥物價值的機會。然而，如果這些努力失敗，可能會導致「自然後果」。
The FDA's Peter Marks made the remarks Thursday at the Jefferies London Healthcare Conference. Marks is the current director of the Center for Biologics Evaluation and Research (CBER) at the FDA. The center ensures the safety and effectiveness of biological products, including vaccines.
FDA的彼得·馬克斯（Peter Marks）在倫敦傑弗裏醫療會議上發表了上述評論。馬克斯是FDA生物製品評價與研究中心（CBER）的現任董事。該中心確保生物製品的安全性和有效性，包括生物-疫苗。
Marks said now is the chance for scientists to make the case for vaccines, as Trump has named noted anti-vaccine crusader Robert F. Kennedy Jr. as his pick to be the next Secretary of Health and Human Services.
馬克斯表示，現在是科學家爲生物-疫苗辯護的機會，因爲特朗普已任命著名反疫苗鬥士羅伯特·F·肯尼迪（Robert F. Kennedy Jr.）爲下任衛生與公共服務部長的候選人。
Bloomberg is also reporting that Trump is likely to pick surgeon and public health researcher Marty Makary as the next head of the FDA. Previously, Makary has criticized the agency's approval of COVID-19 booster vaccines. Additionally, he has written several op-eds on the pandemic including one claiming that the U.S. would achieve herd immunity by April 2021 and a more recent one arguing that vaccines shouldn't be recommended universally for lower-risk patients.
彭博社還報道，特朗普可能會選擇外科醫生和公共衛生研究員馬蒂·馬卡里（Marty Makary）作爲下任FDA局長。之前，馬卡里曾批評該機構對COVID-19加強針的批准。此外，他還撰寫了幾篇關於疫情的社論，包括一篇聲稱美國將在2021年4月實現群體免疫的文章，以及一篇更近期的文章，論證生物-疫苗不應普遍推薦給低風險患者。
Marks said that if public health officials fail to make the case for vaccines there will be consequences.
馬克斯表示，如果公共衛生官員未能爲生物-疫苗做出辯護，將會有所後果。
"If that doesn't work, and everything runs wild in the opposite direction, just as your kids learn natural consequences — if you put your hand on a hot oven, you will get burned, et cetera, that kind of thing — the American public will learn the natural consequences of what happens if vaccination rates fall too far, because we will start to see measles, polio, things that we should never see in a well-developed country, come back," said Marks, who was speaking virtually at the conference, STAT reported.
"如果那不起作用，一切都朝着相反的方向發展，就像你的孩子們學習自然後果一樣——如果你把手放在熱烤箱上，你會被燒到，等等——美國公衆將學習如果疫苗接種率過低會發生的自然後果，因爲我們將開始看到麻疹、脊髓灰質炎等在發達國家不該看到的疾病復發，"馬克斯在會議上虛擬發言時說，STAt報道。
Marks said he expects a vigorous debate on COVID-19 vaccines and pediatric vaccines but hopes a "degree of moderation will prevail" on the topic of vaccines overall.
馬克斯表示，他預計會對COVID-19生物-疫苗和兒童生物-疫苗展開激烈辯論，但希望在整體生物-疫苗話題上能保持一定程度的溫和。
譯文內容由第三人軟體翻譯。
